March 5, 2021 07:30 AM EST
Coronavirus

Brii Bio joins the NIH grave­yard along­side GSK, Lil­ly af­ter flop­ping an­ti­body study in hos­pi­tal­ized Covid-19 pa­tients

Max Gelman

Senior Editor

Just a day af­ter Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s Covid-19 an­ti­body fell flat in an NIH-spon­sored tri­al for hos­pi­tal­ized pa­tients, re­searchers have eject­ed an­oth­er ther­a­py …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times